Evidence map›Paper›PMID 30446799›Full record

ArticleWorld journal of urology2019

Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories.

Matthew Mossanen, Ye Wang, Julie Szymaniak, Wei Shen Tan, Melissa J Huynh, Mark A Preston, Quoc-Dien Trinh, Guru Sonpavde, Adam S Kibel, Steven L Chang

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Economic Impact of Bladder Cancer in the USA.PharmacoEconomics - open · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Matthew MossanenDivision of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA. mmossanen@bwh.harvard.edu.
Ye WangCenter for Surgery and Public Health, Brigham and Women's Hospital, Boston, MA, USA.
Julie SzymaniakDivision of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA.
Wei Shen TanUniversity College of London, London, England, UK.
Melissa J HuynhDivision of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA.
Mark A PrestonDivision of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA.
Quoc-Dien TrinhDivision of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA.
Guru SonpavdeDana-Farber Cancer Institute, Boston, MA, USA.
Adam S KibelDivision of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA.
Steven L ChangDivision of Urology, Harvard Medical School, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNon-muscle-invasive bladder cancer (NMIBC) is a biologically heterogeneous disease and is one of the most expensive malignancies to treat on a per patient basis. In part, this high cost is attributed to the need for long-term surveillance. We sought to perform an economic analysis of surveillance strategies to elucidate cumulative costs for the management of NMIBC.

methodsA Markov model was constructed to determine the average 5-year costs for the surveillance of patients with NMIBC. Patients were stratified into low, intermediate, and high-risk groups based on the EORTC risk calculator to determine recurrence and progression rates according to each category. The index patient was a compliant 65-year-old male. A total of four health states were utilized in the Markov model: no evidence of disease, recurrence, progression and cystectomy, and death.

resultsCumulative costs of care over a 5-year period were $52,125 for low-risk, $146,250 for intermediate-risk, and $366,143 for high-risk NMIBC. The primary driver of cost was progression to muscle-invasive disease requiring definitive therapy, contributing to 81% and 92% of overall cost for intermediate- and high-risk disease. Although low-risk tumors have a high likelihood of 5-year recurrence, the overall cost contribution of recurrence was 8%, whereas disease progression accounted for 71%.

conclusionAlthough protracted surveillance cystoscopy contributes to the expenditures associated with NMIBC, progression increases the overall cost of care across all three patient risk groups and most notably for intermediate- and high-risk disease patients.

Indexed as

Health Care CostsAgedHumansMaleNeoplasm InvasivenessRisk AssessmentUrinary Bladder NeoplasmsBladder cancerCostsMarkov modelNon-muscle invasiveSurveillance

Identifiers

PMID30446799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.